Your product is now available from Integrated DNA Technologies.
Many of the Swift products you have grown to love are now part of our new complete portfolio, xGen™ NGS. Through this new partnership we are pleased to offer you comprehensive next generation sequencing solutions.
xGen NGS—made for you.
Unsure of what products are available? Or, perhaps you’d like guidance on which products are compatible? If so, try our xGen NGS Solutions Builder Tool today.
Welcome to the IDT family!
Find Archer now at IDT!
All Archer information is now available on IDT’s website. You can view Archer assays alongside IDT’s xGen™ NGS portfolio to find the best next generation sequencing solution for your lab.
Confidently detect more with Archer NGS assay solutions for your solid tumor, blood cancer, immune profiling, and genetic disease research.
Choose your region, country/territory, and preferred language
Frequently asked questions
Our Scientific Applications Support team has assembled a list of frequently asked questions to help you find answers quickly. Filter using one or more categories to focus on specific topics, or use the search bar to perform a text search.
Search all FAQs:
Is the PAM sequence part of the CRISPR-Cas9 crRNA construct?
No. The PAM sequence is located on the non-complementary strand. That is, it is on the strand of DNA that contains the same DNA sequence as the target crRNA . The PAM sequence should not be included in the design of the crRNA.
The most commonly used Cas9 nuclease, derived from S. pyogenes, recognizes a PAM sequence of NGG that is found directly downstream of the target sequence in the genomic DNA, on the non-target strand.